{'fraction_non_alphanumeric': 0.028545941123996433, 'fraction_numerical': 0.013380909901873328, 'mean_word_length': 5.678571428571429, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Clinical aspects of treatment of genital herpes with plaferon LB and phenowine].

Exacerbation of genital herpes simplex is followed by suppression of immunocompetence of patients. This proves necessity of adjuvant immunocorrective therapy. In our previous investigations it was shown that plaferon LB possessed immunotropic effect, and phenowine (as an antioxidant remedy) was intensifying the action of plaferon. These data allow us to examine protective action of plaferon and phenowine in complex treatment of genital herpes. High-performance scheme of herpetic relapse was suggested, which was established on aetiotropic effect of acyclovir and immunomodulating action of plaferon and phenowine: satisfactory outcome in 92,1 percent (monotherapy with acyclovir--70,7%). Results of complex therapy appeared in reduction of period of acute infection (on average 2,3 days) and in prolongation of remission (on average 157,3 days, vs 88,5 days in control group). Therapeutic action was achieved by antiviral properties of acyclovir and plaferon, immunostimulating action of plaferon and antioxidant effect of phenowine.